Covered recipient · General Payments record
JONATHAN LAWRENCE QUILES
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Adult Health
General Payments · PY2023–2024
$1,165.83
- Reported across 58 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $678.75 | 37 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $293.52 | 16 |
| GlaxoSmithKline, LLC. | $193.58 | 12 |
| Novo Nordisk AS | $135.77 | 6 |
| PFIZER INC. | $34.87 | 2 |
| Acerta Pharma LLC | $21.01 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (37)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $27.10 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108049021 | CMS |
| ABBVIE INC. | $25.35 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108049023 | CMS |
| ABBVIE INC. | $31.39 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108049025 | CMS |
| ABBVIE INC. | $26.23 | 03/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108049027 | CMS |
| ABBVIE INC. | $9.43 | 04/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108049029 | CMS |
| ABBVIE INC. | $26.39 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108049031 | CMS |
| ABBVIE INC. | $8.85 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108049033 | CMS |
| ABBVIE INC. | $6.76 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108049035 | CMS |
| ABBVIE INC. | $28.07 | 06/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108049037 | CMS |
| ABBVIE INC. | $8.04 | 07/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108049039 | CMS |
| ABBVIE INC. | $4.22 | 07/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108049041 | CMS |
| ABBVIE INC. | $32.79 | 08/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108049043 | CMS |
| ABBVIE INC. | $24.68 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108049045 | CMS |
| ABBVIE INC. | $3.91 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108049047 | CMS |
| ABBVIE INC. | $18.59 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108049049 | CMS |
| ABBVIE INC. | $11.72 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108049051 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.01 | 04/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105873511 | CMS |
| GlaxoSmithKline, LLC. | $23.38 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116431495 | CMS |
| GlaxoSmithKline, LLC. | $12.95 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116386318 | CMS |
| GlaxoSmithKline, LLC. | $23.76 | 02/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115957576 | CMS |
| GlaxoSmithKline, LLC. | $1.85 | 02/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116242071 | CMS |
| GlaxoSmithKline, LLC. | $13.94 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116555191 | CMS |
| GlaxoSmithKline, LLC. | $16.59 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116444246 | CMS |
| GlaxoSmithKline, LLC. | $13.46 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116241297 | CMS |
| GlaxoSmithKline, LLC. | $17.89 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116581323 | CMS |
| GlaxoSmithKline, LLC. | $18.42 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116054200 | CMS |
| GlaxoSmithKline, LLC. | $22.51 | 11/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116178171 | CMS |
| GlaxoSmithKline, LLC. | $15.37 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116319942 | CMS |
| GlaxoSmithKline, LLC. | $13.46 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116011501 | CMS |
| Novo Nordisk Inc | $22.00 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100241800 | CMS |
| Novo Nordisk Inc | $19.99 | 03/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100598577 | CMS |
| Novo Nordisk Inc | $22.88 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100268514 | CMS |
| Novo Nordisk Inc | $23.35 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100261099 | CMS |
| Novo Nordisk Inc | $23.57 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100641798 | CMS |
| Novo Nordisk Inc | $23.98 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100453276 | CMS |
| PFIZER INC. | $17.66 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131074535 | CMS |
| PFIZER INC. | $17.21 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131171945 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.